MEDCITY

Contract research organizations make good money providing critical services to young biotech and drug development companies early on. But often, those companies are cash-strapped at the stage when they need a CRO. That’s why some CROs are becoming stakeholders in the companies they work with, offering cash or services for equity in life science startups…

It was nice to hear one healthcare executive and investor after another respond to the question, “what are your key priorities when evaluating a deal?” with the answer, “really compelling science.”

I’ve often heard VCs and angel investors cite the importance of large addressable markets and talented executive teams as key considerations to a deal, along with compelling technology. But the different dynamics among different investors really came to the surface at today’s Life Science Nation’s Redefining Early-Stage Investments conference in Boston, which focused on alternative sources of funding…